Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com -- Biomerica Inc (NASDAQ:BMRA) stock surged 30.4% after the UAE Ministry of Health and Prevention approved the company’s Fortel Ulcer Test for home use in the country.
The approval allows UAE residents to self-administer the 10-minute rapid diagnostic test that detects antibodies to Helicobacter pylori (H. pylori), a bacterium responsible for peptic ulcers and a significant portion of gastric cancer cases.
H. pylori affects approximately 41% of the UAE population, with up to 20% of infected individuals potentially developing serious complications if left untreated. The World Health Organization has classified H. pylori as a Class 1 carcinogen and listed it among the top antibiotic-resistant bacterial threats.
"With this home-use approval, we’re giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications," said Zack Irani, CEO of Biomerica. "This can help drive earlier and more effective medical treatment and potentially save lives."
The company is now partnering with UAE-based distributors and healthcare providers to make the test available at pharmacies, clinics, and online platforms. This approval strengthens Biomerica’s presence in the Middle East, building on the previous regional launch of its EZ Detect Colon Disease Test.
Biomerica focuses on delivering affordable diagnostic tools that improve patient outcomes through early disease detection. The company’s products are designed to be accessible and effective for global health improvement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.